Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Localization of 99mTc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological Responses.

Kaloudi A, Lymperis E, Kanellopoulos P, Waser B, de Jong M, Krenning EP, Reubi JC, Nock BA, Maina T.

Pharmaceuticals (Basel). 2019 Mar 20;12(1). pii: E42. doi: 10.3390/ph12010042.

2.

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients.

Daly A, Rostomyan L, Betea D, Bonneville JF, Villa C, Pellegata NS, Waser B, Reubi JC, Waeber Stephan C, Christ E, Beckers A.

Endocr Connect. 2019 Mar 1. pii: EC-19-0004.R1. doi: 10.1530/EC-19-0004. [Epub ahead of print]

3.

The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist.

Abiraj K, Ursillo S, Tamma ML, Rylova SN, Waser B, Constable EC, Fani M, Nicolas GP, Reubi JC, Maecke HR.

EJNMMI Res. 2018 Aug 2;8(1):75. doi: 10.1186/s13550-018-0428-y.

4.

New Gastrin Releasing Peptide Receptor-Directed [99mTc]Demobesin 1 Mimics: Synthesis and Comparative Evaluation.

Nock BA, Charalambidis D, Sallegger W, Waser B, Mansi R, Nicolas GP, Ketani E, Nikolopoulou A, Fani M, Reubi JC, Maina T.

J Med Chem. 2018 Apr 12;61(7):3138-3150. doi: 10.1021/acs.jmedchem.8b00177. Epub 2018 Mar 19.

PMID:
29517903
5.

A Critical Evaluation of sst3 and sst5 Immunohistochemistry in Human Pituitary Adenomas.

Körner M, Waser B, Christ E, Beck J, Reubi JC.

Neuroendocrinology. 2018;106(2):116-127. doi: 10.1159/000472563. Epub 2017 Apr 7.

PMID:
28384628
6.

PET/CT Imaging of Unstable Carotid Plaque with 68Ga-Labeled Somatostatin Receptor Ligand.

Wan MYS, Endozo R, Michopoulou S, Shortman R, Rodriguez-Justo M, Menezes L, Yusuf S, Richards T, Wild D, Waser B, Reubi JC, Groves A.

J Nucl Med. 2017 May;58(5):774-780. doi: 10.2967/jnumed.116.181438. Epub 2016 Dec 8.

7.

Approaches to improve metabolic stability of a statine-based GRP receptor antagonist.

Popp I, Del Pozzo L, Waser B, Reubi JC, Meyer PT, Maecke HR, Gourni E.

Nucl Med Biol. 2017 Feb;45:22-29. doi: 10.1016/j.nucmedbio.2016.11.004. Epub 2016 Nov 4.

PMID:
27865999
8.

Highly Increased 125I-JR11 Antagonist Binding In Vitro Reveals Novel Indications for sst2 Targeting in Human Cancers.

Reubi JC, Waser B, Mäcke H, Rivier J.

J Nucl Med. 2017 Feb;58(2):300-306. doi: 10.2967/jnumed.116.177733. Epub 2016 Aug 25.

9.

Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers.

Rylova SN, Waser B, Del Pozzo L, Tönnesmann R, Mansi R, Meyer PT, Reubi JC, Maecke HR.

J Nucl Med. 2016 Aug;57(8):1282-8. doi: 10.2967/jnumed.115.168948. Epub 2016 Apr 28.

10.

Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate Cancer.

Gourni E, Del Pozzo L, Kheirallah E, Smerling C, Waser B, Reubi JC, Paterson BM, Donnelly PS, Meyer PT, Maecke HR.

Mol Pharm. 2015 Aug 3;12(8):2781-90. doi: 10.1021/mp500671j. Epub 2015 Jul 15.

PMID:
26132879
11.

Preoperative localization of adult nesidioblastosis using ⁶⁸Ga-DOTA-exendin-4-PET/CT.

Christ E, Wild D, Antwi K, Waser B, Fani M, Schwanda S, Heye T, Schmid C, Baer HU, Perren A, Reubi JC.

Endocrine. 2015 Dec;50(3):821-3. doi: 10.1007/s12020-015-0633-7. Epub 2015 May 23. No abstract available.

PMID:
26001537
12.

Stereochemistry of amino acid spacers determines the pharmacokinetics of (111)In-DOTA-minigastrin analogues for targeting the CCK2/gastrin receptor.

Kolenc Peitl P, Tamma M, Kroselj M, Braun F, Waser B, Reubi JC, Sollner Dolenc M, Maecke HR, Mansi R.

Bioconjug Chem. 2015 Jun 17;26(6):1113-9. doi: 10.1021/acs.bioconjchem.5b00187. Epub 2015 May 20.

PMID:
25971921
13.

Neurotensin receptors in pancreatic ductal carcinomas.

Körner M, Waser B, Strobel O, Büchler M, Reubi JC.

EJNMMI Res. 2015 Mar 24;5:17. doi: 10.1186/s13550-015-0094-2. eCollection 2015.

14.

Triple-peptide receptor targeting in vitro allows detection of all tested gut and bronchial NETs.

Reubi JC, Waser B.

J Nucl Med. 2015 Apr;56(4):613-5. doi: 10.2967/jnumed.114.153189. Epub 2015 Feb 19.

15.

Does somatostatin or gastric inhibitory peptide receptor expression correlate with tumor grade and stage in gut neuroendocrine tumors?

Körner M, Waser B, Reubi JC.

Neuroendocrinology. 2015;101(1):45-57. doi: 10.1159/000371804. Epub 2015 Jan 12.

16.

Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas.

Waser B, Blank A, Karamitopoulou E, Perren A, Reubi JC.

Mod Pathol. 2015 Mar;28(3):391-402. doi: 10.1038/modpathol.2014.113. Epub 2014 Sep 12.

17.

N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging.

Gourni E, Mansi R, Jamous M, Waser B, Smerling C, Burian A, Buchegger F, Reubi JC, Maecke HR.

J Nucl Med. 2014 Oct;55(10):1719-25. doi: 10.2967/jnumed.114.141242. Epub 2014 Aug 21.

18.

[111In-DOTA]LTT-SS28, a first pansomatostatin radioligand for in vivo targeting of somatostatin receptor-positive tumors.

Maina T, Cescato R, Waser B, Tatsi A, Kaloudi A, Krenning EP, de Jong M, Nock BA, Reubi JC.

J Med Chem. 2014 Aug 14;57(15):6564-71. doi: 10.1021/jm500581d. Epub 2014 Jul 23.

PMID:
25007399
19.

PEG spacers of different length influence the biological profile of bombesin-based radiolabeled antagonists.

Jamous M, Tamma ML, Gourni E, Waser B, Reubi JC, Maecke HR, Mansi R.

Nucl Med Biol. 2014 Jul;41(6):464-70. doi: 10.1016/j.nucmedbio.2014.03.014. Epub 2014 Mar 29.

PMID:
24780298
20.

The glucose-dependent insulinotropic polypeptide receptor: a novel target for neuroendocrine tumor imaging—first preclinical studies.

Gourni E, Waser B, Clerc P, Fourmy D, Reubi JC, Maecke HR.

J Nucl Med. 2014 Jun;55(6):976-82. doi: 10.2967/jnumed.113.133744. Epub 2014 Apr 17.

21.

Radiolabelled GLP-1 receptor antagonist binds to GLP-1 receptor-expressing human tissues.

Waser B, Reubi JC.

Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1166-71. doi: 10.1007/s00259-013-2684-4. Epub 2014 Feb 12.

PMID:
24519555
22.

[DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting.

Tatsi A, Maina T, Cescato R, Waser B, Krenning EP, de Jong M, Cordopatis P, Reubi JC, Nock BA.

Eur J Med Chem. 2014 Feb 12;73:30-7. doi: 10.1016/j.ejmech.2013.12.003. Epub 2013 Dec 16.

PMID:
24378707
23.

Syntheses, receptor bindings, in vitro and in vivo stabilities and biodistributions of DOTA-neurotensin(8-13) derivatives containing β-amino acid residues - a lesson about the importance of animal experiments.

Sparr C, Purkayastha N, Yoshinari T, Seebach D, Maschauer S, Prante O, Hübner H, Gmeiner P, Kolesinska B, Cescato R, Waser B, Reubi JC.

Chem Biodivers. 2013 Dec;10(12):2101-21. doi: 10.1002/cbdv.201300331.

PMID:
24327436
24.

Early over-expression of GRP receptors in prostatic carcinogenesis.

Körner M, Waser B, Rehmann R, Reubi JC.

Prostate. 2014 Feb;74(2):217-24. doi: 10.1002/pros.22743. Epub 2013 Oct 22.

PMID:
24150752
25.

Evolution of bombesin conjugates for targeted PET imaging of tumors.

Zhang H, Abiraj K, Thorek DL, Waser B, Smith-Jones PM, Honer M, Reubi JC, Maecke HR.

PLoS One. 2012;7(9):e44046. Epub 2012 Sep 14.

26.

[(99m)Tc]Demomedin C, a radioligand based on human gastrin releasing peptide(18-27): synthesis and preclinical evaluation in gastrin releasing peptide receptor-expressing models.

Nock BA, Cescato R, Ketani E, Waser B, Reubi JC, Maina T.

J Med Chem. 2012 Oct 11;55(19):8364-74. doi: 10.1021/jm300741f. Epub 2012 Sep 26.

PMID:
22966957
27.

Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications.

Fani M, Braun F, Waser B, Beetschen K, Cescato R, Erchegyi J, Rivier JE, Weber WA, Maecke HR, Reubi JC.

J Nucl Med. 2012 Sep;53(9):1481-9. doi: 10.2967/jnumed.112.102764. Epub 2012 Jul 31.

28.

Secretin receptor promotes the proliferation of endocrine tumor cells via the PI3K/AKT pathway.

Lee M, Waser B, Reubi JC, Pellegata NS.

Mol Endocrinol. 2012 Aug;26(8):1394-405. doi: 10.1210/me.2012-1055. Epub 2012 Jun 12.

29.

[111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study.

Tatsi A, Maina T, Cescato R, Waser B, Krenning EP, de Jong M, Cordopatis P, Reubi JC, Nock BA.

EJNMMI Res. 2012 Jun 9;2(1):25. doi: 10.1186/2191-219X-2-25.

30.

Phosphorylation of sst2 receptors in neuroendocrine tumors after octreotide treatment of patients.

Waser B, Cescato R, Liu Q, Kao YJ, Körner M, Christ E, Schonbrunn A, Reubi JC.

Am J Pathol. 2012 May;180(5):1942-9. doi: 10.1016/j.ajpath.2012.01.041.

31.

Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting.

Körner M, Waser B, Schonbrunn A, Perren A, Reubi JC.

Am J Surg Pathol. 2012 Feb;36(2):242-52. doi: 10.1097/PAS.0b013e31823d07f3.

32.

Novel dimeric DOTA-coupled peptidic Y1-receptor antagonists for targeting of neuropeptide Y receptor-expressing cancers.

Chatenet D, Cescato R, Waser B, Erchegyi J, Rivier JE, Reubi JC.

EJNMMI Res. 2011 Sep 2;1(1):21. doi: 10.1186/2191-219X-1-21.

33.

Glucose-dependent insulinotropic polypeptide receptors in most gastroenteropancreatic and bronchial neuroendocrine tumors.

Waser B, Rehmann R, Sanchez C, Fourmy D, Reubi JC.

J Clin Endocrinol Metab. 2012 Feb;97(2):482-8. doi: 10.1210/jc.2011-2454. Epub 2011 Nov 23.

PMID:
22112810
34.

Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro.

Cescato R, Waser B, Fani M, Reubi JC.

J Nucl Med. 2011 Dec;52(12):1886-90. doi: 10.2967/jnumed.111.095778. Epub 2011 Nov 8.

35.

Characterization of a novel five-transmembrane domain cholecystokinin-2 receptor splice variant identified in human tumors.

Sanchez C, Escrieut C, Clerc P, Gigoux V, Waser B, Reubi JC, Fourmy D.

Mol Cell Endocrinol. 2012 Feb 26;349(2):170-9. doi: 10.1016/j.mce.2011.10.010. Epub 2011 Oct 25.

PMID:
22040601
36.

Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy.

Waser B, Beetschen K, Pellegata NS, Reubi JC.

Neuroendocrinology. 2011;94(4):291-301. doi: 10.1159/000330447. Epub 2011 Sep 2.

PMID:
21893952
37.

N-imidazolebenzyl-histidine substitution in somatostatin and in its octapeptide analogue modulates receptor selectivity and function.

Erchegyi J, Cescato R, Waser B, Rivier JE, Reubi JC.

J Med Chem. 2011 Sep 8;54(17):5981-7. doi: 10.1021/jm200307v. Epub 2011 Aug 16.

PMID:
21806016
38.

PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.

Fani M, Del Pozzo L, Abiraj K, Mansi R, Tamma ML, Cescato R, Waser B, Weber WA, Reubi JC, Maecke HR.

J Nucl Med. 2011 Jul;52(7):1110-8. doi: 10.2967/jnumed.111.087999. Epub 2011 Jun 16.

39.

Concomitant vascular GRP-receptor and VEGF-receptor expression in human tumors: molecular basis for dual targeting of tumoral vasculature.

Reubi JC, Fleischmann A, Waser B, Rehmann R.

Peptides. 2011 Jul;32(7):1457-62. doi: 10.1016/j.peptides.2011.05.007. Epub 2011 May 13.

PMID:
21605611
40.

On the terminal homologation of physiologically active peptides as a means of increasing stability in human serum--neurotensin, opiorphin, B27-KK10 epitope, NPY.

Seebach D, Lukaszuk A, Patora-Komisarska K, Podwysocka D, Gardiner J, Ebert MO, Reubi JC, Cescato R, Waser B, Gmeiner P, Hübner H, Rougeot C.

Chem Biodivers. 2011 May;8(5):711-39. doi: 10.1002/cbdv.201100093.

PMID:
21560227
41.

Comparison of the binding and internalization properties of 12 DOTA-coupled and ¹¹¹In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607.

Aloj L, Aurilio M, Rinaldi V, D'ambrosio L, Tesauro D, Peitl PK, Maina T, Mansi R, von Guggenberg E, Joosten L, Sosabowski JK, Breeman WA, De Blois E, Koelewijn S, Melis M, Waser B, Beetschen K, Reubi JC, de Jong M.

Eur J Nucl Med Mol Imaging. 2011 Aug;38(8):1417-25. doi: 10.1007/s00259-011-1816-y. Epub 2011 Apr 20.

PMID:
21523391
42.

Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor.

Kolenc-Peitl P, Mansi R, Tamma M, Gmeiner-Stopar T, Sollner-Dolenc M, Waser B, Baum RP, Reubi JC, Maecke HR.

J Med Chem. 2011 Apr 28;54(8):2602-9. doi: 10.1021/jm101279a. Epub 2011 Apr 1.

PMID:
21456601
43.

High expression of NPY receptors in the human testis.

Körner M, Waser B, Thalmann GN, Reubii JC.

Mol Cell Endocrinol. 2011 Apr 30;337(1-2):62-70. doi: 10.1016/j.mce.2011.01.021. Epub 2011 Feb 2.

PMID:
21295110
44.

Value of the radiolabelled GLP-1 receptor antagonist exendin(9-39) for targeting of GLP-1 receptor-expressing pancreatic tissues in mice and humans.

Waser B, Reubi JC.

Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1054-8. doi: 10.1007/s00259-010-1701-0. Epub 2011 Jan 6.

45.

Neuropeptide Y acts within the rat testis to inhibit testosterone secretion.

Allen CD, Waser B, Körner M, Reubi JC, Lee S, Rivier C.

Neuropeptides. 2011 Feb;45(1):55-61. doi: 10.1016/j.npep.2010.10.006. Epub 2010 Nov 26.

46.

One-step ¹⁸F-labeling of carbohydrate-conjugated octreotate-derivatives containing a silicon-fluoride-acceptor (SiFA): in vitro and in vivo evaluation as tumor imaging agents for positron emission tomography (PET).

Wängler C, Waser B, Alke A, Iovkova L, Buchholz HG, Niedermoser S, Jurkschat K, Fottner C, Bartenstein P, Schirrmacher R, Reubi JC, Wester HJ, Wängler B.

Bioconjug Chem. 2010 Dec 15;21(12):2289-96. doi: 10.1021/bc100316c. Epub 2010 Nov 17.

PMID:
21082773
47.

Glucagon-like peptide-1 (GLP-1) receptors are not overexpressed in pancreatic islets from patients with severe hyperinsulinaemic hypoglycaemia following gastric bypass.

Reubi JC, Perren A, Rehmann R, Waser B, Christ E, Callery M, Goldfine AB, Patti ME.

Diabetologia. 2010 Dec;53(12):2641-5. doi: 10.1007/s00125-010-1901-y. Epub 2010 Sep 14.

48.

Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours.

Mansi R, Wang X, Forrer F, Waser B, Cescato R, Graham K, Borkowski S, Reubi JC, Maecke HR.

Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):97-107. doi: 10.1007/s00259-010-1596-9. Epub 2010 Aug 18.

PMID:
20717822
49.

Absence of somatostatin SST(2) receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model.

Waser B, Cescato R, Tamma ML, Maecke HR, Reubi JC.

Eur J Pharmacol. 2010 Oct 10;644(1-3):257-62. doi: 10.1016/j.ejphar.2010.07.005. Epub 2010 Jul 16.

PMID:
20643121
50.

Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog.

Reubi JC, Erchegyi J, Cescato R, Waser B, Rivier JE.

Eur J Nucl Med Mol Imaging. 2010 Aug;37(8):1551-8. doi: 10.1007/s00259-010-1445-x. Epub 2010 Apr 16.

Supplemental Content

Support Center